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ABSTRACT
Gastroesophageal reflux disease (GERD) is a condition commonly managed in the primary care setting. 
Patients with GERD may develop reflux esophagitis as the esophagus repeatedly is exposed to acidic gastric 
contents. Over time, untreated reflux esophagitis may lead to chronic complications such as esophageal 
stricture or the development of Barrett’s esophagus (BE). BE may progress to oesophageal adenocarcinoma. 
There is currently a rising incidence of BE. The pathogenesis of BE is not well-understood although genetic 
and environmental factors play significant roles. BE is characterized by the replacement of distal esophageal 
stratified squamous epithelium by columnar epithelium. It is rare in children and the risk factors may include 
mental retardation, cerebral palsy, esophageal atresia, etc. As patients with BE can be entirely asymptomatic, 
it is difficult to screen this population group. BE is present in 10–20% of patients with GERD and has also been 
detected in patients who deny classic GERD symptoms and are undergoing endoscopy for other indications.
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ABSTRAK
Penyakit refluks gastroesophageal (GERD) adalah kondisi umum yang dikelola dalam perawatan primer. 
Pasien dengan GERD dapat berkembang menjadi refluks esofagitis akibat asam lambung yang kembali ke 
esophagus berulang kali. Seiring waktu, reflux esophagitis yang tidak diobati dapat menyebabkan komplikasi 
kronis seperti striktur esofagus atau berkembang menjadi Barrett’s esophagus (BE). BE dapat berkembang 
menjadi adenokarsinoma esofagus. Saat ini kejadian BE semakin meningkat. Patogenesis BE belum dipahami 
dengan baik meskipun faktor genetik dan lingkungan memainkan peran yang signifikan. BE ditandai dengan 
perubahan sel epitel skuamosa berlapis di distal esofagus oleh sel epitel kolumnar. BE jarang terjadi pada 
anak-anak dan faktor-faktor risiko yang mungkin pada anak-anak yaitu keterbelakangan mental, cerebral palsy, 
atresia esofagus, dll. Pasien dengan BE bisa sepenuhnya asimtomatik sehingga sangat sulit untuk diskrening 
pada populasi. 10 -20% pasien dengan GERD bisa menjadi BE dan juga bisa terjadi pada pasien dengan gejala 
GERD klasik yang disangkal dan sedang menjalani endoskopi untuk indikasi lain.
Kata kunci: Gastroesophageal reflux disease (GERD), Barrett’s esophagus, adenokasinoma esofagus
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INTRODUCTION
Barrett’s esofagus (BE) is a metaplastic condition 
where columnar epithelium was replaced by squamous 
epithelium in distal part of esophagus. BE is the 
main risk factor of esophageal adenocarcinoma and 
gastroesophageal junction adenoma.1
Prevalence of BE in population was estimated 
around 1.6-1.7%. In 2000 at US, about 3.3 million 
of individual were reported to have this condition. 
In GERD patients, incidence of BE is 5-10%, while 
patients with esophageal peptic stricture have almost 
30% incidence of BE. BE was found to be higher 
among male with ratio 3:1 to female.2-4 Detection and 
treatment of BE is currently challenging. As the main 
risk factors of esophageal cancer, BE patients have 40 
times risk compared to population.5,6
Esophageal cancer prevalence was increasing in 
recent years, especially among Western Countries. 
In Asia, most of the etiology of esophageal cancer 
is squamous cell carcinoma. Studies reported that 
progression of BE to esophageal cancer is progressively 
increasing in Asia as the prevalence of BE increasing.7
INCIDENCE BARRETT’S ESOPHAGUS
Incidence of BE among white race in developed 
countries were constant in recent two decades (studies 
published at 1990 and 2005). The first study report 
incidence in Minnesota with majority of Scandinavian, 
Germany, and other Europeans. In the second study 
conducted in Swedish, the sample population was 
quite larger. Therefore, both epidemiologic data were 
considered accurate to represent population.8,9
A prospective study in Minnesota for 18 months 
from 1986-1987 conducted an esophageal specimen 
autopsies, choosen if having more than 3 cm of 
mucosal layer with salmon-like colour. From 733 
subjects, 7 were having severe long-segment Barrett 
Esophagus with prevalence of 376 per 100.000 cases 
or 0.34.8-10 Incidence of long-segment BE in Asia is 
low (<1 % from all BE patients), while short-segment 
BE is high, approximately 96%.7
RISK FACTORS OF BARRETT’S ESOPHAGUS
Age
Since BE is an acquired disease, its incidence is 
increasing by age. Mean age of clinical diagnosis are 
63 years old. Long-segment BE is rarely found in 
children. In a recent cohort study, 8 from 166 child 
receiving long term proton pump inhibitor treatment 
developed BE, mostly in patients with chronic 
gastroesophageal reflux with impaired mental status 
and having predisposing risk factors such as down 
syndrome or cerebral palsy.8-10
There were shifting trends of BE incidence relatet 
to age which mostly found in age above 70 years old. 
Pathophysiology of BE migh be different in Asia 
(mostly short-segment) and in Western (mostly long-
term).7
In a review article by Suzanne et al in 2011, there 
were four cohort studies that showed 37 pediatric 
patients developed BE at mean 12.4 years old, mostly 
caused by GERD. Other 14 studies reported mean age 
of 9.5 years old. BE was diagnosed approximately 5 
years after GERD symptoms detected.11
Gender
A study in Mayo Clinic on patients underwent 
endoscopy at 1976-1989 reported that long-segment 
BE were found higher in male compared to female. A 
multicenter study in Italy at 1987-1989, BE ratio in 
male to female is 2.6.7
Ethnicity and geography
Long-segment BE were found higher in Western 
countries. In a retrospective cohort study of 2100 
individuals (37.7% white race, 11.8% black race, and 
22.2% hispanic), BE prevalence were 6.1%, 1.6%, and 
1.7%, respectively.7
Reflux
Around 15-20% adult in US were reported a history 
of heartburn once a week and 7% among them felt it 
every day. In GERD patients, 3-7% were found to have 
BE on endoscopic examination, while it only 1-2% 
in non-GERD patients. 12 In individuals complaining 
heartburn twice or more a week, BE were foun in 7 
of 378 patients (1.8%) after endoscopic examination. 
Patients with short-segment BE will have more reflux 
symptoms.12
PATHOPHYSIOLOGY OF BARRETT’S ESOPHAGUS
The main etiology of BE is unknown, but GERD 
is the main risk factors of the disease. Although 
not all patients with GERD will developed BE, 3 
from 5 BE patients have history of GERD. BE is 
the major predisposition condition for esophageal 
adenocarcinoma.13
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GERD is a serious condition of gastroesophageal 
reflux (GER). GER occurred when lower esophageal 
sphingter spontaneously open in several occasion and 
do not completely closing, so that gastric content would 
reach to esophagus. GER also known as acid reflux or 
acid regurgitation because of digestion enzyme follow 
gastric content during reflux.13
In BE, there were metaplasial changes from 
columnar epithelium to squamous epithelium in 
distal esophagus. Hiatal hernia, weakness of lower 
esophageal sphincter, and acid exposure in esophageal 
is common in BE patients compared to normal 
population. Researchers hypothize that hiatal hernia 
and impaired lower esophageal sphincter as the 
beginning process to develop metaplasia as seen in 
Figure 1.7,12,14,15 
There was a direct causal between duration of 
acid exposure in esophagus and severity of mucosal 
damage. Increase exposure of acid was among the 
etiology of mechanical defect in lower esophageal 
sphincter and also reduce its contraction rhythm. This 
dysmotility imparted reflux material clearing so that 
contact time will be increasing.6,12
Several experimental data showed that not only 
gastric acid that damage esophageal mucose but also 
pepsin. Acid reflux contribute to metaplasia process 
but not act as the main etiology. Other duodenal 
materials such as pancreatic enzymes, bile secretion, 
and lysolechitin were also played an important role in 
intestinal metaplasia and malignancy process. Pepsin 
and tripsin damage mucosa by its proteolytic effect. In 
acidic condition, pepsin and tripsin altered intracellular 
junction thus lead to epithelial breaks. Bile secretion 
impaired both cell and intraceullar organ functions. 
Otherwise, gastric acid is needed to activate several 
enzymes such as pepsinogen and also enhance bile 
secretion impact on mucosa. In neutral pH condition, 
deconjucated bile secretion have more destruction effect 
compared to conjugated. Deconjugated bil secretion 
were formerly precipitating in neutral pH condition.7,12,14
Inflammation that results from chronic reflux might 
be a key to the development of BE. Damaged mucosal 
layer was infiltrated by inflammatory cell, mainly T 
lymphocyte in metaplasial area.7,14
Inflammatory cells infiltration also induce 
production of reactive oxygen species (ROS). ROS 
implicated in cell cycle, signal transduction, protein 
degreadation, and also DNA repair process.7,14 ROS 
induce cytokine production that stimulate epithelial 
proliferation, survival, and also migration. This 
inflammatory response involving growth factor-β, 
interleukin-1β, IL-10, IL-4, interferon-γ and TNF-α. 
This showed that there are specific cytokines reaction 
to mucosal damaged by reflux.7,14
Individual with esophagitis would have acute 
inflammatory response via Th-1 cell with increasing 
IL-1β, IL-8 and IFN-γ level. This response was related 
to common cellular immune response to infection 
or malignancy. Cytokine Th-2 increase IL-10 and 
IL-4 and laso related to BE which induce goblet cell 
metaplasia and mutation in mucin gen in respiratory 
epithelial cells. 7,14
Figure 1. Pathogenesis of GERD to the development of metaplasia (Barrett’s esophagus)15
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In biomolecular area, transformation of squamous 
epithelium to Barret metaplasia were not fully known, 
but recent studies showed several key areas involving 
morphogenic factors and homeobox (HOX) gene 
which encode transcription factors of intestinal 
epithelium. BE was a consequence of chronic GERD, 
so that caudal Homeobox (CDX) gene expression were 
hypothize as the basic molecular mechanism of the 
disease pathogenesis, as shown in Figure 2.16
Expression of CDX, bone morphogenetic protein 
(BMP)-4, and other morphogenetic factors in basal 
cell or stromal cell would mediate metaplastic process 
from squamous cell into columnar cell, thus BE cell 
express CDX1 and CDX2 higher than normal cells. 
Hypothetically, there are two ways how GERD might 
induce CDX expression: (1) Stimulation from gastric 
content (acid, bile salt); (2) Inflammation of esophagus 
(esophagitis).16
ENDOSCOPIC CLASSIFICATION OF BARRETT’S 
ESOPHAGUS
Classification of Barrett’s esophagus based on 
endoscopic and biopsy were divided into three main 
categories: long-segment, short segment, and cardiac 
intestinal metaplasia. Previously, Barrett’s esophagus 
only classified based on its segment size (≥ 3 cm or ≤ 
3 cm), while cardiac intestinal metaplasia was defined 
as intestinal metaplasia in gastroesophageal junction. 
Cut off value of 3 cm were used since 1970 to prevent 
overdiagnosis if physician fail to recognize gastric 
herniation during endoscopy procedure. The size of 
barrett’s esophagus do not correlate significantly to risk 
of adenocarcinoma and do not have clinical importance.17
Figure 2. Scheme representing how GERD results in Barrett’s esophagus 
development16
Figure 3. Barret's Esophagus17 
Figure 4. A. Short segment. B Long Segment Barret's Esophagus. A' B' Endoscopic view17 
Figure 3. Barret's Esophagus17 
Figure 4. A. Short segment. B Long Segment Barret's Esophagus. A' B' Endoscopic view17 
Figure 3. Barret’s esophagus17
Figure 4. A. Short segment. B Long segment Barret’s esophagus. 
A’ B’ endoscopic view17
Z-line classification wer  used to know extension 
of short segment BE during endoscopy. This system 
also used 3 cm as the cut off to differ between Grade 
Figure 3. Barret's Esophagus17 
Figure 4. A. Short segment. B Long Segment Barret's Esophagus. A' B' Endoscopic view17 
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II and Grade III, but proven to be inaccurate to 
predict progression or regression of BE. The recent 
classification, known as Prague criteria C and M, is 
now being used by clinician. This system use circular 
diameter (C) and maximum distance (M), as shown in 
Figure 5 below. 18
Prague C and M were firtly introduced by Sharma 
et al. This classification was used during endoscopic 
examination. It has good prediction value when the 
lesion size is above 1 cm.18
CLINICAL MANIFESTATION OF BARRETT’S 
ESOPHAGUS
Principally, BE is asymptomatic. The most common 
complaint of BE patients is the symptom of GERD, 
such as heartburn or regurgitation. It is difficult to 
differ between BE and GERD only by its symptom. 
Individuals who had GERD symptoms for more than 
5 years were at higher possiblility to develop BE. 
Therefore, GERD patients with unimproved symptoms 
for 5 years were recommended to undergo endoscopic 
examination.19
Rex et al (2003) found that almost 8% of BE have a 
history of heartburn (compared to normal population, 
6%), while Ward et al (2006) found 20% and 15%, 
respectively. In a meta analysis by Cook et al, reflux 
symptoms were foung in 8-20% of BE patients.3,19
DIAGNOSIS OF BARRETT’S ESOPHAGUS
Diagnosis of BE was based on history taking, 
physical examination, and supporting examination. 
History taking should be specific to clinical features of 
BE: heartburn (81%), dysphagia (51%), regurgitation 
(35%), chest pain, hematemesis, and melena, while 
23-40% among them is asymptomatic and 10-19% do 
not have reflux symptoms.19 Other risk factors of BE 
are white race, male, and adult age.19
Endoscopy
With only standard endoscopy procedure, it is 
difficult to distinguish between cancer and precancer 
lesion. Only 10% of GERD patients who had BE and 
those individuals need to have routine endoscopic 
examination to monitor the progression into malignancy 
lesion. Gold standard of BE diagnosis is upper GI tract 
endoscopy and recommended only in patients with 
chronic reflux (above 5 years) or unimproved GERD.20
Normally, junctional area between gastric columnar 
epithelium and esophageal squamous epithelium is 
found in distal part of esophagus. In BE, this junction 
is found more proximal so that it is easier to recognize. 
Other endoscopic examination should to investigate the 
correlation between its lesion and esophagitis reflux, 
esophageal ulcer, stricture, hiatal hernia, or nodul/ mass 
suggestive of malignancy.21
Biopsy
In general, BE were consist of three main epithel: 
1) columnar (intestinal metaplasia); (2) gastric (gastric 
epithel); (3) junctional. Although debatable, intestinal 
metaplasia were considered as gold standard of BE. 
In these intestinal metaplasia, Goblet cell could be 
found.22
Figure 6. Barrett’s esophagus dysplasia/neoplasia23
(A)  Barrett esophagus, negative for dysplasia. Hematoxylin and Eosin stain ×200;
(B)  Barrett esophagus with low grade dysplasia. Hematoxylin and Eosin stain ×200;
(C)  Barrett esophagus with high grde dysplasia. Hematoxylin and Eosin stain ×200;
(D) Barrett esophagus with intramucosal adenocarcinoma. Hematoxylin and 
      Eosin stain ×100.
Figure 5. Endoscopic findings showed a salmon-like mucosa 
with distal extension (suspected of Barrett’s esophagus). Prage 
C (yellow) and M (blue) were estimated to be 2 cm and 4 cm, 
respectively18
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Pathologist played an important role in BE 
evaluation by examining its dysplasia from biopsy 
result. Dysplasia was defined as atypical neoplastic 
epithel. Biopsy result was evaluated according to 
surface of the glands, atypical cytology, and the 
presence of inflammation/erosion. There were four 
main categories of BE: negative for dysplasia (NDS); 
indefinite for dysplasia (IND); low-grade dysplasia 
(LGD) and high-grade dysplasia (HGD) as seen in 
Figure 6.23
Negative for dysplasia (NDS): the BE mucosa 
shows maturation characterized by dark-staining nuclei 
with stratification at the base of glands as compared 
to the surface where nuclei are paler, maintain 
polarity and lack stratification. The cytologic atypia 
is limited to the basal portion of glands.23 Indefinite 
for dysplasia (IND): the BE mucosa shows changes 
in deeper glands suggestive with dysplasia, however, 
the surface maturation is preserved. Cytologic atypia 
includes nuclear hyperchromasia, nuclear membrane 
irregularities and increased mitosis.23 Low-grade 
dysplasia (LGD): the Barrett’s mucosa shows loss 
of surface maturation and distortion with glandular 
crowding, without active inflammation. There is a 
difference between neoplastic and non-neoplastic 
mucosa. Nuclei show hyperchromasia, enlargement, 
stratification and mucin loss.23
High-grade dysplasia: the Barrett’s mucosa shows 
loss of surface maturation (as in LGD) and glandular 
crowding. The nuclei show loss of polarity and are 
rounded, enlarged, hyperchromatic with inconspicuous 
nucleoli. Mitoses are frequent. Inflammation is less in 
comparison to the architectural and cytologic atypia.23 
Intramucosal adenocarcinoma defined as invasive 
carcinoma to lamina propria but do not infiltrate to 
muscularis mucosa layer, presented as single cell and 
a small group in lamina propria.23
Based on American College of Gastroenterology, 
diagnosis of BE should follow: (1) BE should be 
diagnosed when there is extension of salmon-colored 
mucosa into the tubular esophagus extending ≥ 1 cm 
proximal to the gastroesophageal junction (GEJ) with 
biopsy confi rmation of IM (strong recommendation, 
low level of evidence); (2) Endoscopic biopsy should 
not be performed in the presence of a normal Z 
line or a Z line with < 1 cm of variability (strong 
recommendation, low level of evidence); (3) In the 
presence of BE, the endoscopist should describe the 
extent of metaplastic change including circumferential 
and maximal segment length using the Prague classifi 
cation (conditional recommendation, low level of 
evidence); (4)  The location of the diaphragmatic hiatus, 
GEJ, and squamocolumnar junction should be reported 
in the endoscopy report (conditional recommendation, 
low level of evidence); (5) In patients with suspected 
BE, at least 8 random biopsies should be obtained to 
maximize the yield of IM on histology. In patients with 
short (1–2 cm) segments of suspected BE in whom 
8 biopsies may be unobtainable, at least 4 biopsies 
per cm of circumferential BE, and one biopsy per cm 
in tongues of BE, should be obtained (conditional 
recommendation, low level of evidence); (6) In patients 
with suspected BE and lack of IM on histology, a repeat 
endoscopy should be considered in 1–2 years of time 
to rule out BE (conditional recommendation, very low 
level of evidence).
MANAGEMENT OF BARRETT’S ESOPHAGUS
Three main targets for BE managements are: (1) 
stop reflux; (2) induce repair or regression of epithel 
metaplasia in order to prevent risk of metaplasia; (3) 
inhibit the development of dysplasia and cancer. Most 
of BE patients were treated using pharmacological 
treatment, but sometimes it is inadequate due to 
lower esophageal sphincter dysfunction and impaired 
esophageal motility function. Medical therapy was 
based on diet, lifestyle changes, promotility agents, 
and acid repressing therapy.20
Role of PPI in BE Management
PPI do not improve symptoms if BE had present, 
although it could decrease disease extension. PPI 
regiment twice a day was allowed with target pH of 
< 4 in most patients until symptoms were controlled.3
Gerson et al reported that reflux severity in BE is 
worse compared to GERD patients. Yeh et al reported 
that reflux symptom control using PPI is not effective 
and 62% among patients had severe gastric acidity during 
night although it symptoms had been controlled. Gerson et 
al that investigate using three different PPI found gastric 
pH < 4 in patients receiving omeprazole, lansoprazole, 
and rabeprazole are 46%, 71%, and 51%, respectively.3
Endoscopic-based Management
Ablation therapy using endoscopy in BE patients 
were indicated in uncontrolled reflux after medical 
or surgical treatment. It has been previously reported 
that ablation therapy is effective in randomized 
controlled trial.24 BE management using endoscopy 
could be classified as using histological examination 
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(endoscopic mucosal resection [EMR] and endoscopic 
submucosal dissection) and ablation therapy. Ablation 
therapy was further classified as heat-generating 
thermal (Radiofrequency ablation [RFA], multipolar 
electrocoagulation, and argon plasma coagulation) 
and photochemical technique (photodynamic therapy 
[PDT]) and cryotherapy. Multimodality therapy using 
resection followed by ablation therapy to eradicate 
Barret’s epithel was the most used comprehensive 
management in BE.24
Esophagectomy
Surgical management is among the choice of 
therapy in BE. During esophagectomy, surgeons 
resect almost all part of esophagus and only left a 
small part of gaster. Several risk factors of surgery 
are bleeding, infection, and dysfunction in esophagus-
gaster junction. Because of its high risk, this treatment 
options is less considered than other treatment. The 
main benefit of surgical approach is a less further 
routine endoscopic examination.24
EVALUATION AND EDUCATION
How frequent endoscopy should be done were 
based on patient clinical features. If biopsy results 
showed “no dysplasia”, it could be done annually. 
If the next biopsy result is “no dysplasia” again, 
endoscopy could be done once in every three years. 
A finding of “low grade dysplasia” suggest a medical 
treatment of GERD and endoscopic reexamination 
after 6 months. Periodic endoscopic examination was 
aimed to prevent any undetected lesion due to its small 
area of presentation.20 The following table are the time 
recommendation for endoscopy examination:
The principle of education in patients with BE are 
similar to GERD patients. They should avoid fatty 
foods, alcohol, carbonated drinks, lemon, tomato sauce, 
mustard, aspirin, and non-steroid anti-inflammatory 
drugs (NSAID). Patients should also divide its mela 
portion, avoid eating meals 3 hours before sleep, 
elevate head for 6 inches when sleeping, lower body 
weight, and stop smoking. Another lifestyle changes 
that related to improve lower esophageal sphincter 
functions are avoidance of chocolate, caffeine, and 
any type of candies.24
COMPLICATION
High-grade dysplasia mostly preceed esophageal 
cancer. If it is found during endoscopy examination, 
endoscopic ultrasonography (EUs) is recommended 
to evaluate its surgical resectability. Although BE is 
clearly a precancer lesion, only a small proportion of 
patients develop cancer. Researches are now focus 
on risk stratification of which BE patients that need 
routine endoscopic treatment for disease monitoring.20
PROGNOSIS
Long standing GERD had been induce cellular 
changes that lining esophagus in most patients. Risk 
of adenocarcinoma in BE patients approximately 
0.5% every year. Otherwise, the etiology of cancer 
progression is unknown. Periodic endoscopic 
examination is recommended in order to find any sign 
of dysplasia or cancer lesion. Prognosis is mainly based 
on patient functional condition, risk factors, and early 
diagnosis and prompt treatment.25
CONCLUSION
Barrett’s esophagus (BE) is a condition in which 
columnar epithel replace squamous epithel in distal 
part of esophagus. Most of the cases were a sequalae of 
reflux esophagitis that known as the main risk factors 
of adenocarcinoma. Studies showed that BE patients 
had long standing GERD symptoms that conversely 
related to disease progression.
Basically, BE is asymptomatic. Symtpoms found in 
BE patients were related to GERD, such as heartburn 
and regurgitation, so that it is difficult to distinguish 
them. Barium enema are insensitive to detect BE, so 
Figure 7. Surveillance table of endoscopic examination in BE20
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that diagnosis is mainly guided by biopsy via endoscopy.
Three main targets for BE managements are: (1) 
Stop reflux; (2) Induce repair or regression of epithel 
metaplasia in order to prevent risk of metaplasia; (3) 
Inhibit the development of dysplasia and cancer.
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